Canada markets closed

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
25.86+0.71 (+2.82%)
At close: 04:00PM EDT
26.49 +0.63 (+2.44%)
After hours: 07:34PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close25.15
Open25.85
Bid21.58 x 1200
Ask36.45 x 800
Day's Range24.25 - 26.26
52 Week Range21.25 - 96.88
Volume487,307
Avg. Volume818,893
Market Cap1.376B
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateJul 27, 2022 - Aug 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.29
  • GlobeNewswire

    CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction

    Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant OutcomesSOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gimé

  • GlobeNewswire

    In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx

    Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents that are variations of the o

  • GlobeNewswire

    CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference

    Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant MonitoringSOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloS